Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review

American journal of clinical and experimental immunology

Lei Zhang¹ 

[1] Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital, Dongying 257034, Shandong, China

关键词: Posterior reversible encephalopathy syndrome;    mycophenolate mofetil;    systemic lupus erythematosus;    adverse drug event;   

DOI  :  

学科分类：过敏症与临床免疫学

来源: e-Century Publishing Corporation

【 摘 要 】

Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogenic edema secondary to hypertension and endothelial damage. PRES is reversible with withdrawal of the offending agent, strict blood pressure control, and treating the underlying disease. We report present here a patient with lupus nephritis who developed PRES following mycophenolate administration.

【 授权许可】

CC BY-NC